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• cancers : malignant neoplasms , abnormal  uncontrolled division of cells 
• Alternative splicing : a pivotal step in m-RNA maturation , regulate gene expression.
• alternatively spliced products linked to the development of neoplastic diseases (1).
•With powerful techniques and new analyses , AS is a growing and promising field in 
oncology (1).
Splicing regulation 
• in process of AS :exons are selectively included or excluded. 
• relies on combination of cis elements and trans acting factors. 
• Cis elements could be recognized by spliceosome complex(2). 
• It‘s also regulated by auxiliary factors called : the SR proteins(2) and hn-RNP family(2)
• These proteins inhibit or reinforce A.S by recognizing additional regulatory elements 
• SR proteins           enhancers (2)                hn-RNPs          silencers (2)
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Splicing regulation 
• Function of regulatory elements could change depending on state and requirements of the 
cell. 
• DNA methylation in either cis-acting or trans-acting elements is associated with various 
cancers (3).
• The informations elicited from measurement of an A.S event offer diagnostic information
• Regulatory factors and elements can be target to modify an splicing event with therapeutic 
purposes (1).  
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Splicing regulation 
pre-mRNA splicing:The dotted 
lines represent the intron, and the 
boxes are exons. The 5'-splice site 
(5'-SS), the 3'-splice site (3'-SS), and 
the branch point adenosine (BP). 
The conserved residues at the branch 
site and the 5'-and 3'-SS are shown. 
The thin lines are sn-RNAs with 
their names in the ellipses. The 2'-
OH groups of branch point 
adenosine and the cutoff 5' exon are 
pictured in the activated 
spliceosome. The small arrows near 
2'-OH group indicate the 





Types of alternative splicing 
• Exon skipping            an exon is spliced out with its flanking introns. one or several 
exons are not present in final m-RNA , mutations that interfere with exon definition.
• Alternative in the selection of  3' or 5' splice site          two 5' splice site compete for a 
single 3'splice site or visa versa
•
• Mutually exclusive exons            a choice between two alternative exons. A rare 
subtype 
• Intron retention           intron remains in the mature m-RNA transcript . A common
mechanism of tumor-suppressor inactivation .  
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Types of alternative splicing 
• Use of alternative promoters
• Unusual poly-adenylation
• Alternative splicing event coupled with non-sense mediated decay         one of the third 
splicing isoforms. 
• In addition to protein diversity , A.S leads to reduced translation of m-RNA , introduction 
of premature stop codon leading to sequestration and degradation of transcripts into nucleus 
by none sense mediated decay; famous as poison exons (3).
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Types of alternative 
splicing 
Schematic representation of 
different types of RNA splicing.
The dotted grey lines indicate 
the alternative splicing 
processes: a exon
skipping; b, c alternative 3′- and 
5′-SS; d mutually exclusive 
exons;
intron retention; f usage of 







A.S related diseases 
• Aberrant splicing isoforms             direct DNA mutation in cis elements
unbalanced splicing factor expression
mutated splicing factor 
• Cystic fibrosis              mutation in exon 19 leads to a novel donor site , inclusion of 84bp cryptic exon with 
an stop codon , a shorter and nonfuctional protein (4) . 
• Familiar dysautonomia 5' splice site mutation of IKBKAP gene , NMD , down regulation of  cell 
migration-related gene . 
• Fukuyama muscular dystrophy(FCMD)             SVA – transposable elements insertion in 3' UTR , inclusion 
of new exon from SVA sequence , altered c terminus ,nonfunctional protein(5) . 
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A.S related diseases 
• Alzheimer             choice between inclusion and skipping of MAPT exon 10 leads to two tau 
isoforms (6). 
• Betta thalasseamia different point mutations in betta globin gene , reduced production of m-
rna due to abnormal splicing.
• Duchene muscular dystrophy              deletion of exon 49,50,52
• Parkinson disease            The exon 4  deletion created a reading frameshift over the junction of exons 
3–5, a stop codon downstream from exon 3 ,parkin protein loses two-RING finger domain , loss of 
enzymatic activity (7). 
• Neurofibromatosis type 1             Exon 15 and 16 skipping due to weak splicing sites (4 ).
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• Drug resistance 









endogenous RhoA activity 
in MDAMB-
231 cells. MDA-MB-231 
cells





Altered Splicing of FGFR1 is 
associated with high
tumor grade and stage and 
leads to increased
sensitivity to FGF1 in 
bladder cancer
Proliferation 
Identification of FGFR1 splice variants in 
bladder cancer cell lines.
A: Diagrammatic representation of the 
alternative mRNA splice variants ofFGFR1, 
identified by RT-PCR. SP, signal peptide; Ig 
I-III, immunoglobulin-like domains I-III; TM, 
transmembrane domain; TK-1 and TK-
2tyrosine kinase domain.
. B:western blotting confirmed FGFR1 and 




FGF activation of 
FGFR1 induces an 






•Figure 1. Bcl-x and Mcl1 Alternative Splicing 
Reporters (A) Bcl-x and Mcl1 minigene splicing 
reporters are schematized. Green rectangles are 
exons, dark gray as alternative regions. Black lines 
depict introns. Large arrows denote translation 
start sites. Inserted PTCs, exclusive to long (L) 
isoforms, are shown by red ‘‘stop signs.’’ (D) 
SF3B1 knockdown activated proapoptotic splicing 
of Bcl-x and Mcl1 reporters. Stable reporter lines 
were transfected with SF3B1 or nontargeting 
siRNA pools and imaged in the indicated channels. 
SF3B1 knockdown increased minigene expression 
versus controls in both cases. SF3B1 depletion also 
decreased CFP modestly, possibly reflecting a role 
in splicing the EF1a intron. Subsequent 
experiments showed this effect on CFP expression 
















Expression of CD44v in metastatic breast cancer 
cells with lung colonization potential. 
Regulation of alternative splicing of CD44 mRNA 






TRA2A-overexpressing cells formed more colonies 
than control cells when given paclitaxel treatment.
TRA2A silencing in PTXR cells resulted in fewer 





Western blotting showed an 
increase in TRA2A and hn-
RNPm protein levels under
paclitaxel treatment 
compared with normal 
conditions. TRA2A protein 












Distribution of alternative exon usages in AML cells that are resistant 
to anti-cancer drugs. A. Distribution of quantitative and qualitative gene 
modifications in AraC-, DXR- and AZA-resistant cells. Total RNA was 





The clonogenic survival of four cell lines 
following irradiation.
The colony-forming ability was calculated 
by comparing the numbers of
colonies between the irradiated and 
nonirradiated controls. Points, means







transfected cell lines   
Similar pattern of 
increased radiation-
induced apoptosis 







The number of different splicing 
events in the normal and chemo-
radiation-resistant colon cancer 
cells. A3SS, alternative 3' splice 
site;
A5SS, alternative 5' splice site; 
MXE, mutually exclusive exon; 
IR, intron retention; ES, exon 
skipping; RCR-HCT116, chemo-
radiation-resistant HCT116 cells;
MISO, mixture of isoforms; 
RPKM, reads per kilobase million
Strategies to regulate pathogenic A.S in cancer   
• small oligo-nucleotides  antisense oligonucleotides  (ASO) 
splice switching oligonucleotides  (SSO)
Si-RNA
• Protein inhibitors  
• Transposon 
• Small molecules as drugs 
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Small 0ligo-nucleotids 
• Including ASOs            inhibit  synthesis of aberrant m-RNA  
Si-RNA , micro-RNA                RNAase H –mediated cleavage  
SSOs         favor the production of one isoform without impact on gene expression
• ASOs and Si-RNA target an splicing isoform named as ISIs(Isoform-specific inhibitors) group (8).
• In cancer treatment, ASOs can be used to shift a splicing event towards an anti-proliferative isoform.
• splice switching oligonucleotides (SSO), modified A.S  by the steric blocking of trans acting factors and 
reprogram splicing . 
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small oligo-nucleotides 
• SSOs, short oligonucleotides, target specific cis elements within the pre-mRNA compete 
with splicing factors to access these elements
• A decrease in bcl-xL mRNA and protein,  an increase in bcl-xS mRNA and protein was 
observed in cancer cell lines treated with SSOs in a dose-dependent manner.
• Particular applications of SSO   ESSENCE(Exon-specific splicing enhancement
by small chimeric effectors) 
TOSS (Targeted oligonucleotide silencers of splicing)
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small oligo-nucleotides 
• ESSENCE uses an oligo-nucleotide bound to a peptidic RS-domain at the 3'end, 
enhance exon inclusion mediated by SR proteins
• TOSS employs an oligonucleotide with a 5' or 3‘ extension that is recognized by hnRNP
A1/A2 proteins, strongly inhibits splicing at the targeted splice site.
• FDA approved antisense drugs :   Fomivirsen for cytomegalovirus retinitis 
 Mipomersen for homozygous familial hypercholesterolemia   
 Eteplirsen for Duchenne muscular dystrophy 











Expression of h-TERT ASVs in six 
glioma cell lines was detected by RT-
PCR  
Detection of telomeras activity in six 
glioma cell lines by TRAP method 
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small oligo-nucleotides 
Numbers of colony-forming units in 
every group
protein expression levels of pro-
apoptosis and antiapoptosis proteins 
determined by western blotting.
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small olig-onucleotide 
49Effects of eteplirsen on the dystrophin-associated glycoprotein complex
Protein inhibitors 
• Inhibits selected trans acting factors           regulate aberrant A.S event and 
expression ratio  





• TEs are known to be able to exploit available DNA breaks for insertion 
mutations (9).
• Alu elements have exonizations activity , that is, splicing-mediated 
insertions of  Alu sequences into mature mRNAs (10) .
• Internal exons that contain an Alu sequence are alternatively spliced (10) .
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Small molecules as drugs 
• natural compounds and synthetic derivatives as inhibitors that target RNA splicing
• These inhibitors are cytotoxic at higher concentrations, but at low concentration they  use
as drugs for modulating RNA splicing in cancer (3). 
• The earliest splicing modulators were FR901464, a natural product extracted from 
Pseudomonas (11)  .
• discovered to bind to and inhibit the spliceosome component SF3B1, interferes with 
U2SnRNP and preventing the transition of the spliceosome complex A to B (12).
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small molecules as drug 
• Some examples of inhibitor molecules :
Isoginkgetin (7-O-β-D-glucopyranoside)          isolated from dried leaves of Gingko biloba, 
inhibiting the transition from spliceosomal complex A to B at a concentration of 30 nM (2)
Pladienolide B (PB)              a macrocyclic lactone with anti-proliferative activity, PB 
induces cell cycle arrest at both G1 and G2/M by increasing on the expression of p16 and 
cyclin E genes while inducing apoptosis. 
Chlorhexidine phosphorylate SR proteins and it affects the alternative splicing of 
many pre-mRNAs including RON, caspase 9, and HIV Tat2-3
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Small molecules as drug  
• caffeine and digoxin           reduce expression of SRSF3  and increase expression of a 
p53b isoform. accompanied by increased DNA damage and apoptosis (3).
• Sudemycins can regulate the production of alternatively spliced RNA 
transcripts that are more prevalent in tumour . 
• Ibrutinib its role in therapy expanded when FDA  approved its use in  frontline 
and salvage treatment for patients with CLL(13) .
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small molecules as drug 
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Small molecules as drug 
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Small molecule as drugs 
HeLa and H9c2 cells were treated with the 
indicated amount of caffeine for 24 h. The 
morphological changes of HeLa cells were 
monitored
Caffeine induces the alternative 
transcription of the p53 isoform.
Splicing isoforms phenotype in human cell lines 
• To uncover the functions of endogenous splicing isoforms in vitro, three 
complementary class of tools can be used :
ISI            induce a splicing shift and a decrease in global expression   
SM             induce a splicing shift
strategy targeting all isoforms (Global siRNAs or global Gapmers)             decrease 
global expression
61
Splicing isoforms phenotype in human cell lines 
• there are three possible scenarios to illustrate the relationship between two splicing isoforms : 
• scenario 1 : alternative splicing produces an isoform without a functional domain or 
triggering NMD.  one of the two isoforms have a function and its abundance will drive the 
phenotype. 
 SMs, ISIs and global targeting of all isoforms 
• scenario 2: alternative splicing produces an isoform with antagonistic functions. the relative 
abundance of one isoform over the other dictate the phenotype. 
 SMs and ISIs 
• scenario 3: alternative splicing produces an isoform with compensatory function. the overall 
expression level will drive the phenotype.
 ISIs and global targeting of all isoforms
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Splicing isoforms phenotype in human cell lines 
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Methodologies to measure the effectiveness of
isoform-specific tool
• End-point PCR 
The gold standard method to quantify splicing isoform modulation 
two primers are designed , it will generate two PCR products.
Impossible to assess the impact of a SM on the overall gene expression.
• Real-time PCR  
each isoform needs to be amplified in a separate tube.
• Western blotting 
detect the splicing shift at the protein level by western-blot.
64
References 
• 1. Pio R, Montuenga LM. Alternative splicing in lung cancer. Journal of Thoracic Oncology. 
2009;4(6):674-8.
• 2. Martinez-Montiel N, Rosas-Murrieta NH, Anaya Ruiz M, Monjaraz-Guzman E, Martinez-
Contreras R. Alternative splicing as a target for cancer treatment. International journal of 
molecular sciences. 2018;19(2):545..
• 3. Di C, Zhang Q, Chen Y, Wang Y, Zhang X, Liu Y, et al. Function, clinical application, and 
strategies of Pre-mRNA splicing in cancer. Cell Death & Differentiation. 2019;26(7):1181-94.
• 4. Abramowicz Anna1 & Gos Monika1, Splicing mutations in human genetic disorders: 
examples,detection, and confirmation. Journal of Applied Genetics (2018) 59:253–268
• 5. Ravi K.Singh1Thomas A.Cooper , 2012, Pre-mRNA splicing in disease and therapeutics, 
Trends in Molecular Medicine Volume 18, Issue 8, August 2012, Pages 472-48
• 6.   Giuseppe Biamonti1 · Angela Amato1 Elisa Belloni1· Anna Di Matteo1 Lucia Infantino
Davide Pradella1·Claudia Ghigna1, Alternative splicing in Alzheimer’s disease, Aging Clinical 
and Experimental Research,
• 7. Ru-Huei Fu,*† Shih-Ping Liu,*‡ Shyh-Jer Huang,§ Hung-Jen Chen, Aberrant Alternative 
Splicing Events in Parkinson’s Disease, Cell Transplantation, Vol. 22, pp. 653–661, 2013
65
References 
• 8. Jean-Philippe Brosseau, Splicing isoform-specific functional genomic in cancer cell. 
Brosseau Applied Cancer Research (2018) 38:18.
• 9. Newman, Andrew G,Bessa, Paraskevi,Tarabykin, Victor.Singh, Prim B, 2017, 
Activity‐DEPendent Transposition, EMBO reports,18,3 
• 10. Sorek, Rotem ,Ast Gil,Graur Dan, Alu-containing exons are alternatively spliced,
Genome research,2002,7:1088-9051
• 11. Nakajima, H. et al. (1997) New antitumor substances, FR901463, FR901464 and 
FR901465. III. Structures of FR901463, FR901464 and FR901465. J. Antibiot. (Tokyo) 50, 96–
99 
• 12.Corrionero, A. et al. (2011) Reduced fidelity of branch point rec-ognition and alternative 
splicing induced by the anti-tumor drug spliceostatin A. Genes Dev. 25, 445–459 
• 13 . Maliha Khan, et al. Spotlight on ibrutinib and its potential in frontline treatment of chronic 
lymphocytic leukemia. Onco Targets Ther. 2017; 10: 1909–1914.
66
